# US 2010/0137389 A1 · Topical formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137389 A1
- Document ID: US20100137389A1
- Status: Published application
- Kind: A1
- Application number: 12/524,421
- Filed: 2008-01-22
- Published: 2010-06-03
- Earliest claimed: 2007-01-24
- Assignees: Bomac Research Limited
- Inventors: Karthigeyan Nanjan; Fadil Al Alawi; Paul Chambers; Kate Hill
- Web page: https://patentgrep.com/patent/US20100137389A1

## CPC

- A61K 31/4164: 1,3-Diazoles
- A61K 9/0017: {Non-human animal skin, e.g. pour-on, spot-on}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy.

## Claims

### Claim 1

A composition formulated for transdermal administration comprising at least one anti-hyperthyroid drug;
at least one aprotic polar solvent; at least one polyo; and at least one fatty acid.

### Claim 2 (depends on 1)

The composition as claimed in claim 1 wherein the fatty acid is selected from the group consisting of oleic acid, linoleic acid, palmitic acid, and combinations thereof.

### Claim 3 (depends on 1)

The composition as claimed in claim 1 wherein the aprotic polar solvent is selected from the group consisting of
pyrrolidone, dimethylformamide, and combinations thereof.

### Claim 4 (depends on 3)

The composition as claimed in claim 3 wherein the pyrrolidone is selected from the group consisting of n-methyl-pyrrolidone (NMP), 2-pyrrolidone, and combinations thereof.

### Claim 5 (depends on 1)

The composition as claimed in claim 1 wherein the polyol is selected from the group consisting of polypropylene glycol, polyethylene glycol, and combinations thereof.

### Claim 6 (depends on 1)

The composition as claimed in claim 1 further comprising a terpene.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition as claimed in claim 1 further comprising a C2-C8 alcohol.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The composition as claimed in claim 1 further comprising a glycol ether.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The composition as claimed in claim 1 further comprising acetin.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The composition as claimed in claim 1 wherein the antihyperthyroid drug is a thioamide.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The composition as claimed in claim 1 wherein the composition contains approximately 5-10 mg per dose of antihyperthyroid drug.

### Claim 17 (depends on 1)

The composition as claimed in claim 1 wherein the composition is formulated as a viscous gel or ointment.

### Claim 18

A method of treatment of hyperthyroidism in a non-human animal in need thereof comprising transdermal administration of a composition comprising at least one antihyperthyroid drug;
at least one aprotic polar solvent; at least one polyol; and at least one fatty acid.

### Claim at position 19

19-20. (canceled)

### Claim 21

Use of a composition formulated for transdermal administration including at least one antihyperthyroid drug in the manufacture of a medicament for treatment of hyperthyroidism in an animal in need thereof;
wherein the composition further comprises at least one aprotic polar solvent, at least one polyol and at least one fatty acid.

### Claim at position 21

22-23. (canceled)

### Claim 24

A method of manufacturing a composition formulated for transdermal administration comprising the steps of:
(a) heating propylene glycol to a temperature of 50-60° C.;
(b) dissolving PEG 4000 into the propylene glycol;
(c) mixing in at least one compound selected from the group consisting of d-limonene, N-methyl-pyrrolidone, ethanol, triacetin, and combinations thereof;
(d) dissolving in at least one antihyperthyroid drug; and
(e) mixing in oleic acid and cooling.

### Claim at position 23

25-28. (canceled)

### Claim 29 (depends on 18)

The method as claimed in claim 18 wherein the dose of the antihyperthyroid drug is 10 mg per day, administered once a day.
